Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic–induced necroptosis
Burak Uzunparmak, Meng Gao, Antje Lindemann, Kelly Erikson, Li Wang, Eric Lin, Steven J. Frank, Frederico O. Gleber-Netto, Mei Zhao, Heath D. Skinner, Jared Newton, Andrew G. Sikora, Jeffrey N. Myers, Curtis R. Pickering
Burak Uzunparmak, Meng Gao, Antje Lindemann, Kelly Erikson, Li Wang, Eric Lin, Steven J. Frank, Frederico O. Gleber-Netto, Mei Zhao, Heath D. Skinner, Jared Newton, Andrew G. Sikora, Jeffrey N. Myers, Curtis R. Pickering
View: Text | PDF
Research Article Cell biology Oncology

Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic–induced necroptosis

  • Text
  • PDF
Abstract

Caspase-8 (CASP8) is one of the most frequently mutated genes in head and neck squamous carcinomas (HNSCCs), and CASP8 mutations are associated with poor survival. The distribution of these mutations in HNSCCs suggests that they are likely to be inactivating. Inhibition of CASP8 has been reported to sensitize cancer cells to necroptosis, a regulated cell death mechanism. Here, we show that knockdown of CASP8 renders HNSCCs susceptible to necroptosis by a second mitochondria-derived activator of caspase (SMAC) mimetic, birinapant, in combination with pan-caspase inhibitors Z-VAD-FMK or emricasan and radiation. In a syngeneic mouse model of oral cancer, birinapant, particularly when combined with radiation, delayed tumor growth and enhanced survival under CASP8 loss. Exploration of molecular underpinnings of necroptosis sensitivity confirmed that the level of functional receptor-interacting serine/threonine protein kinase 3 (RIP3) determines susceptibility to this mode of death. Although an in vitro screen revealed that low RIP3 levels rendered many HNSCC cell lines resistant to necroptosis, patient tumors maintained RIP3 expression and should therefore remain sensitive. Collectively, these results suggest that targeting the necroptosis pathway with SMAC mimetics, especially in combination with radiation, may be relevant therapeutically in HNSCC with compromised CASP8 status, provided that RIP3 function is maintained.

Authors

Burak Uzunparmak, Meng Gao, Antje Lindemann, Kelly Erikson, Li Wang, Eric Lin, Steven J. Frank, Frederico O. Gleber-Netto, Mei Zhao, Heath D. Skinner, Jared Newton, Andrew G. Sikora, Jeffrey N. Myers, Curtis R. Pickering

×

Figure 5

RIP3 expression is silenced in many HNSCC cell lines, but patient tumors show considerable expression.

Options: View larger image (or click on image) Download as PowerPoint
RIP3 expression is silenced in many HNSCC cell lines, but patient tumors...
(A) Cell lysates obtained from a panel of 5 CASP8WT and 4 CASP8mutant human-derived HNSCC cell lines were subjected to Western blot analysis for caspase-8 and key necroptosis markers; β-actin was used as loading control. Cell lines were treated with birinapant (B [1 μmol/L]), Z-VAD-FMK (Z [5 μmol/L]), necrostatin-1s (N [10 μmol/L]), or the combinations for 24 hours. Cell viability was assessed using CellTiter-Glo. Then, “% necroptosis” was used to assess necroptosis sensitivity for each cell line and calculated based on percentage reduction in cell density with birinapant plus Z-VAD-FMK treatment that was reversible by necrostatin-1s. This is a measure of necroptotic death. Please refer to Supplemental Figure 8 for detailed analysis. (B) Scatter plot shows gene expression for RIP3 in a panel of 80 human-derived HNSCC cell lines. Median with 95% CI values are shown by the bar. Cell lines used for the Western blot analysis were highlighted. (C) RIP3 gene expression in TCGA HPV-negative oral cancer samples. Median with 95% CI values are shown by the bar.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts